A rapid pharmacogenomic assay to detect *NAT2* polymorphisms and guide isoniazid dosing for tuberculosis treatment

Authors: Renu Verma[1], Sunita Patil[1], Nan Zhang[2], Flora Martinez Figueira Moreira[3], Marize Teixeira Vitorio[3], Andrea da Silva Santos[3], Ellen Wallace[4], Devasena Gnanashanmugam[4], David Persing[4], Rada Savic[2], Julio Croda[5,6], Jason R. Andrews[1*]

1. Division of Infectious Diseases and Geographic Medicine, Stanford University School of Medicine, Stanford, CA, USA
2. Department of Bioengineering and Therapeutic Sciences, University of California, San Francisco, CA, USA
3. Federal University of Grande Dourados, Dourados, Brazil
4. Cepheid Inc., Sunnyvale, California, USA
5. Postgraduate Program in Infectious and Parasitic Diseases, Federal University of Mato Grosso do Sul, Mato Grosso do Sul, Brazil
6. Oswaldo Cruz Foundation Mato Grosso do Sul, Mato Grosso do Sul, Brazil

Keywords: tuberculosis; isoniazid; pharmacogenomic; molecular diagnostic; *NAT2*

Abstract Word Count: 183

Word Count: 3,817

Tables: 3

Figures: 4

Reference: 50

Correspondence*

Jason Andrews, MD

Division of Infectious Diseases and Geographic Medicine

Biomedical Innovations Building, Room 3458

Stanford University School of Medicine

Stanford, CA 94305

Email: jandr@stanford.edu

Phone: +1 650 497 2679

Abstract

Treatment of tuberculosis involves use of standardized weight-based doses of antibiotics, but there remains a substantial incidence of toxicities, inadequate treatment response, and relapse, in part due to variable drug levels achieved. Single nucleotide polymorphisms (SNPs) in the N-acetyltransferase-2 *(NAT2)* gene explain 88% of interindividual pharmacokinetic variability of isoniazid, one of the two most important antitubercular antibiotics. A major obstacle to implementing pharmacogenomic guided dosing is the lack of a point-of-care assay. We trained an acetylation genotype classification model from a global dataset of 5,738 genomes, which achieved 100% accuracy in out-of-sample prediction on unphased SNPs from 2,823 samples using 5 SNPs. On a clinical dataset of 49 patients with tuberculosis, we found that a 5 SNP assay accurately predicted acetylation ratios and isoniazid clearance. We then developed a cartridge-based molecular assay for the 5 SNPs on the GeneXpert platform, which enabled accurate classification of allele patterns directly from as little as 25 ul of whole blood. An automated pharmacogenomic assay on a platform widely used globally for tuberculosis diagnosis could enable improved dosing of isoniazid, averting toxicities and improving treatment outcomes.

INTRODUCTION

Despite the availability of effective chemotherapeutic regimens for treatment and prevention of tuberculosis, a substantial proportion of patients experience toxicities, fail treatment or develop recurrent disease[1-3]. Standardized, weight-based dosing of anti-tuberculosis treatment has been the conventional approach to therapy, despite mounting evidence that inter-individual variability in metabolism leads to highly variable drug levels[4,5]. High drug levels are strongly associated with risk of toxicity, while low drug levels are a determinant of treatment failure, slow response, and emergence of drug resistance. Hepatotoxicity is the most common adverse effect, affecting up to 33% of patients receiving standard four-drug therapy[6] and leading to regimen changes in up to 10% of patients[7]. This toxicity is associated with increased costs, morbidity, and occasional mortality, particularly among HIV co-infected individuals[8]. Additionally, as many as 3% of new tuberculosis cases experience treatment failure, and between 6-10% relapse within 2 years[9,10] Pharmacokinetic variability to a single drug is associated with treatment failure and acquired drug resistance[11,12]. One recent study found that individuals with at least one drug below the recommended AUC threshold had a 14-fold increased risk of poor outcomes.[13]

There has been an increasing number of genetic markers identified that predict metabolism and toxicities from various antimicrobials. Isoniazid (INH) is among the most well characterized of these, with 88% of its pharmacokinetic variability explained by mutations in the gene encoding arylamine N-acetyltransferase 2 (NAT2), responsible for acetylation in the liver[14]. Individuals can be classified into three phenotypes—rapid, intermediate, and slow acetylators—according to whether they carry polymorphisms on neither, one, or both copies of this gene, respectively. Rapid acetylators typically have the lowest plasma INH concentrations, while slow acetylators

have high concentrations. A worldwide population survey on *NAT2* acetylation phenotype reported that more than half of the global population are slow or rapid acetylators[15]. Numerous studies have investigated the relationship between acetylation genotype or phenotype and clinical outcomes of tuberculosis treatment. A recent meta-analysis found that rapid acetylators are twice as likely to have microbiological failure and acquired drug resistance[16]. Additional meta-analyses have identified a three- to four-fold increased risk of hepatotoxicity among slow acetylators[17,18]. A recent randomized trial of pharmacogenomic guided dosing for tuberculosis treatment found that, compared with standard dosing, it reduced hepatotoxicity among slow acetylators and increased treatment response at 8 weeks among rapid acetylators[19]

Despite this evidence, pharmacogenomic testing and guided treatment has not entered the mainstream of clinical practice for tuberculosis. Few clinical laboratories perform *NAT2* genotyping, and such testing is not widely available in resource-constrained environments where the majority of tuberculosis burden falls. To address this gap, we developed a prototype *NAT2* pharmacogenomic (NAT2-PGx) assay on a commercial, automated PCR platform (GeneXpert) to detect *NAT2* polymorphisms. We further developed an in-house algorithm to predict INH metabolism phenotype from unphased single nucleotide polymorphism (SNP) patterns, derived from globally representative genomic data. We demonstrate that this tool can accurately predict INH clearance rates directly from clinical samples.

RESULTS

SNP selection and development of acetylation prediction model

Complete phased data for the seven known polymorphisms (191G>A, rs1801279; 282C>T, rs1041983; 341T>C, rs1801280; 481C>T, rs1799929; 590G>A, rs1799930; 803A>G, rs1208; and 857G>A, rs1799931) altering *NAT2* gene function were available for 8,561 individuals from 59 populations. The dataset contains 3,573 (41.7%) individuals with the slow genotype, 3,428 (40.0%) individuals with the intermediate genotype, and 1,560 (18.2%) individuals with the rapid genotype (See **Table 1**). The highest proportion of rapid acetylators were in East Asia (40%), and three regions had prevalence of slow acetylator phenotypes over 50% (Central and South Asia, Europe and North Africa).

We used these phased allele data to select SNPs for inclusion in an assay measuring unphased SNPs. Using a random forest model trained on two thirds of the data (n=5,738), out-of-sample phenotype prediction accuracy from unphased data on the remaining one third (n=2,823) was 100% for models using 7, 6 or 5 SNPs. With 4 SNPs, prediction accuracy was 98.0% (95% CI: 97.4-98.5%), and a 3 SNP model had similar performance (98.0%; 95% CI: 97.4-98.4%) (**Table 2**). However, both of these models performed poorly on data from Sub-Saharan Africa (4 SNP model accuracy: 82.5%, 95% CI: 78.1-86.4%); 3 SNP model accuracy: 81.3%, 95% CI: 76.8-85.3%). Based on these results, we selected the 5 SNP model (191G>A, 282C>T, 341T>C, 590G>A and 857G>A) to take forward for clinical validation and diagnostic development.

Genotype correlation with isoniazid clearance in patients with tuberculosis

We enrolled a cohort of 49 patients with newly diagnosed pulmonary tuberculosis and collected plasma at 1 hour and 8 hours after dose on day 1 and at 1 hour after dose on day 14. To detect five NAT2 polymorphisms identified by our classifier, we performed single-plex PCR assays on 49 sputum samples using molecular beacon probes developed in-house (see Methods). Additionally, we used commercial 7-SNP single-plex genotyping assays and compared the results with 5-SNP single-plex PCR to validate the melt curve accuracy. There was 100% concordance in terms of SNP detection between 5-SNP and commercial 7-SNP assays. Of the 49 individuals for whom NAT2 genotypes were profiled, ΔTm (°C) between wild-type and mutant alleles for positions 191, 282, 341, 590 and 857 were found to be 4.38, 4.04, 2.40, 3.63 and 3.68 respectively. Both mutant and wild type probes had a minimum 2.40°C Tm difference which allowed SNP calling with high accuracy **(Table 3).**

We further predicted phenotypes from 5-SNP using the algorithm described above as well as a publicly available tool (NAT2Pred)[20], which uses 6 SNPs. Among the 49 participants, predicted acetylator types from the 5 SNP assay were: 28 (57%) slow, 16 (33%) intermediate and 5 (10%) rapid. NAT2Pred classified 4 samples as intermediate that were classified as rapid (n=1) or slow (n=3) by the 5 SNP classifier. Among those classified as slow by the 5 SNP classifier and intermediate by NAT2Pred, acetyl-INH to INH ratios at 8 hours were 0.61, 0.38, 0.41, consistent with slow acetylation (median: 0.77, range 0-1.55) rather than intermediate acetylation (median 6.67, range 3.32-22.21) and suggesting misclassification by NAT2Pred. The sample classified as intermediate by NAT2PRed and rapid by the 5 SNP classifier had an acetyl-INH to INH ratio of 9.8, which fell between the median values, and within both ranges, for intermediate and rapid acetylators (range 8.09 - ∞) (**Supplementary Table-1**). Phenotypes predicted by the 5 SNP

139 classifier were strongly predictive of INH acetylation and clearance (**Figure 1a and 1b**). INH
140 clearance rates were lowest in slow acetylators (median 19.3 L/hr), moderate in intermediate
141 acetylators (median 41.0 L/hr) and highest in fast acetylators (median 46.7 L/hr).
142
143 **Development of an automated pharmacogenomic assay**
144
145 Using the primers and probes sequences validated on FAM-labelled single-plex assays targeting
146 five *NAT2* polymorphisms, we developed a 5-plex multiplex assay using the FleXible Cartridge
147 system on the GeneXpert platform, which enables automated extraction, real-time PCR, melt
148 curve analysis and interpretation in 140 minutes (**Figure 2**). We performed the assay on 20
149 whole blood samples from healthy individuals. Mutant, wild-type and heterozygous alleles were
150 manually called based on peak patterns and Tm values detected in melt curves. Negative
151 derivative transformed melt curves from five *NAT2* gene polymorphisms are shown in **Figure 3**.
152 The genotype data generated on GeneXpert was validated by Sanger sequencing. The assay
153 detected all polymorphisms with 100% accuracy (average SD in Tm across all probes = 0.34°C).
154 The NAT2 genotypes corresponding to 20 blood samples covered all three categories - mutant,
155 wild-type and heterozygous for five NAT2 positions except for NAT2-191 for which all samples
156 were all wild-type. Among the 20 samples, predicted acetylator types using the 5-SNP classifier
157 were: 8 (40%) slow, 10 (50%) intermediate and 2 (10%) rapid (**Supplementary Table 2a**).
158
159 We used whole blood samples from ten healthy volunteers to assess the analytic performance of
160 the NAT2-PGx assay at lower sample volumes. The samples at decreasing volumes (200ul,
161 100ul, 50ul and 25ul) were analyzed until the point where all melt peaks could be accurately

detected by GeneXpert. Our assay could accurately detect all melt peaks with as low as 25ul of sample volume. The variability in Tm from five NAT2 probes for sample volumes 200ul-25ul is shown in **Figure 4**. NAT2 polymorphisms were accurately detected at all volumes (**Supplementary Table 2b).**

DISCUSSION

Despite availability of effective treatment for drug-sensitive tuberculosis, a substantial proportion of population encounters drug associated toxicity or treatment failure, much of which could be averted through dosing guided by genetic markers of drug metabolism[21,22]. We previously found that pharmacogenomic guided dosing of isoniazid could be highly cost-effective in low- and middle-income countries[23]. A major barrier to its implementation has been the lack of a simple, scalable assay that could be used at points of care where tuberculosis is treated in resource-constrained settings. To address this gap, we used globally representative genomic data to identify patterns of 5 SNPs that enable accurate prediction of isoniazid acetylator phenotype, validating this with pharmacokinetic data of patients receiving tuberculosis treatment. We then developed a prototype automated pharmacogenomic assay on the GeneXpert platform, which is widely available globally but had never been applied to pharmacogenomics. We found that this assay could robustly distinguish wild type, mutant and heterozygous alleles from a range of blood volumes as low as 25 ul, making it suitable for use with venous blood samples or finger-stick blood samples. The assay requires minimal hands-on time for sample preparation, which would facilitate its use in resource-constrained settings.

An earlier model ("NAT2Pred") predicted NAT2 acetylation phenotype from unphased genomic data; however, it had moderate error rates in distinguishing intermediate from rapid acetylators[24]. Moreover, error rates among individuals from Sub-Saharan Africa were 14%, in part due to the exclusion of the G191A (R64Q) SNP, common to the NAT2 *14 allele cluster, which is frequent in Africans and African-Americans, but virtually absent in Caucasian, Indian, and Korean

190 populations[25]. Indeed, striking ethnic differences in the frequencies of SNPs
191 (http://snp500cancer.nci.nih.gov) are responsible for the differences in frequency of rapid,
192 intermediate and slow acetylator *NAT2* alleles or haplotypes and therefore phenotypes[15, 26, 27]. We
193 trained our SNP classifier with globally representative data, which resulted in the selection and
194 inclusion of the G191A SNP in our model and assay. This is particularly important as Sub-
195 Saharan Africa bears a substantial burden of tuberculosis disease and mortality as well as HIV
196 co-infection, which is independently associated with greater pharmacokinetic variability and
197 tuberculosis treatment toxicity[28-31].
198
199 The association between acetylation polymorphisms and isoniazid metabolism was first
200 demonstrated in 1959, and their importance was well characterized in subsequent decades
201 through phenotypic descriptions[32-34]. Subsequent genotypic descriptions confirmed that NAT2
202 polymorphisms predicted isoniazid early bactericidal activity, and clinical outcomes including
203 hepatotoxicity, relapse and acquisition of drug resistance. Further dosing studies demonstrated
204 that provision of lower doses to slow acetylators and higher doses to rapid acetylators could
205 achieve target concentrations[35]. One randomized trial of pharmacogenomic-guided dosing of
206 isoniazid during active tuberculosis treatment found that it significantly reduced toxicities
207 (among slow acetylators) and treatment non-response (among rapid acetylators). Taken together,
208 the evidence for pharmacogenomic guided dosing to achieve consistent drug levels and improve
209 clinical outcomes is strong. Automated, easy-to-use assays could enable pharmacogenomic
210 guided isoniazid dosing in resource constrained settings, where a substantial burden of the
211 world's tuberculosis occurs.
212

The findings of this study are subject to several limitations. We tested the assays on 49 individuals with active tuberculosis and 20 healthy individuals with a diverse representation of polymorphisms, but the number of participants with G191A mutations was limited (n=5). A larger validation study involving testing on whole blood, including from finger stick capillary blood, is needed to assess real-world performance of this assay under field conditions. Further studies should also investigate testing on non-invasive samples including saliva or oral swabs, from which DNA is abundant. Second, we focused on NAT2 polymorphisms, as they explain 88% of interindividual pharmacokinetic variability, though polymorphisms in several other genes have been associated with hepatotoxicity. However, these associations have been comparatively modest and somewhat inconsistent[36-40]. We focused on isoniazid and did not include other important tuberculosis drugs, such as rifampicin. The evidence base for pharmacogenomic markers predicting rifampin pharmacokinetics is less robust, and findings concerning clinical outcomes such as toxicities or treatment response are limited[41,42]. However, given the importance of this drug class in treatment of active and latent tuberculosis, and emerging evidence supporting greater efficacy of higher doses of rifampin, further investigation of pharmacogenomic markers in rifampicin is needed. Future assays may include polymorphisms influencing rifampicin metabolism to further optimize treatment of tuberculosis.

Since the demonstration of the efficacy of six month, short-course chemotherapy in 1979, standardized treatment for drug susceptible tuberculosis using weight-based doses has remained essentially unchanged[43]. Additionally, isoniazid remains a major component of regimens for treatment of latent tuberculosis, which is recommended by the WHO for young children, HIV-infected individuals and household contacts of tuberculosis cases[44] .More than half the world's

236 population have slow or rapid acetylation phenotypes, which put them at risk for excessive drug
237 levels resulting in drug toxicities or insufficient drug levels putting them at risk of acquired drug
238 resistance or disease relapse. Dose adjustment based on NAT2 acetylation genotyping can
239 achieve consistent, target drug levels and reduce the incidence of poor clinical outcomes. We
240 developed a prototype automated, cartridge-based assay that can reliably predict acetylation
241 phenotype directly from as low as 25 ul of whole blood. By developing this for the GeneXpert
242 platform, which is widely used in low- and middle-income countries for tuberculosis diagnosis,
243 this assay could make personalized tuberculosis treatment dosing available in resource-
244 constrained settings. Further studies are needed to evaluate its accuracy and clinical impact in
245 real-world clinical settings.
246
247 **METHODS**
248
249 **Ethics statement**
250 The clinical study was approved by the institutional review boards of the Stanford University
251 School of Medicine and Federal University of Grande Dourados (IRB#33005). All participants
252 were over the age of 18 and provided written informed consent. For assay optimization and
253 validation on GeneXpert cartridge, anonymized blood samples from healthy individuals were
254 obtained from Stanford blood center.
255
256 **Datasets**

The datasets used to develop the NAT2 classifier was obtained from the IGSR (International Genome Sample Resource, 1000 genomes project) and a meta-analysis by Sabbagh et. al[4,25]. Population information on the combined dataset is provided in **Supplementary Table 3.**

NAT2 acetylator phenotype prediction classifier

Phased genomes from 8,561 individuals were used and haplotypes were labeled based on 7 polymorphic sites in the *NAT2* gene (191G>A, 282C>T, 341T>C, 481C>T, 590G>A, 803A>G and 857G>A), following an international consensus nomenclature (43). Individuals with two slow haplotypes were considered slow acetylators; those with two rapid haplotypes were considered rapid acetylators; and those with one slow and one rapid acetylator were considered intermediate acetylators. We then constructed an unphased dataset containing only information on whether each sample was wild type for both alleles, homozygous variant for both alleles, or heterozygous. We then split the dataset into two-thirds for a training set and one third for an out-of-sample test set, using sampling stratified by geographic representation to ensure representativeness in the training and test sets. We trained a random forest model on the training set using the *caret* package in R[45] and assessed classification performance on the test set. We began with a 7 SNP model and eliminated SNPs in sequential models according to the lowest variable importance factor.

Sample collection

Sputum and plasma samples from 49 newly diagnosed patients with active pulmonary tuberculosis were collected at the Federal University of Grande Dourados, Brazil. All participants were treated with standardized, weight-based doses of isoniazid, rifampicin,

279 pyrazinamide and ethambutol. Plasma samples were collected at 1 hour and 8 hours after the first
280 dose and after 1 hour on day 14. Plasma drug concentrations for isoniazid and acetyl-isoniazid
281 were quantified by high-performance liquid chromatography coupled to tandem mass
282 spectrometry (HPLC-MS) as previously described.[46]
283
284 **Reference NAT2 SNP genotyping assays**
285 *Sputum processing, host DNA extraction and single-plex assays on clinical samples*
286 Spontaneously expectorated sputum from confirmed pulmonary tuberculosis patients was
287 collected in approximately 10mL of guanidine thiocyanate (GTC) solution (5 M guanidinium
288 thiocyanate, 0.5% w/v sodium N-lauryl sarcosine, 25 mM trisodium citrate, 0.1 M 2-
289 mercaptoethanol, 0.5% w/v Tween 80 [pH 7.0]) as described previously[47]. The samples were
290 needle sheared and centrifuged at 3000 rpm for 30 min. The supernatant was removed leaving
291 behind 1ml pellet. The pellet was centrifuged at 11,500 rpm for 3 min. Approximately 0.5 ml
292 supernatant was transferred to a fresh cryovial and 0.75 ml Trizol LS was added to the
293 supernatant. The samples were frozen at -80 until used. Host DNA was extracted from the
294 supernatant using a manual extraction method described previously[48]. The DNA was eluted in 50
295 ul DNase-free water and quantified on Qubit. Approximately 10 ng of genomic DNA was used
296 for each single-plex melt curve and commercial TaqMan SNP (NAT2 TaqMan® SNP
297 Genotyping Assays, Applied Biosystems) assay.
298
299 *DNA extraction from whole blood samples from healthy individuals*

For 5-plex assay validation, genomic DNA from 100ul of whole blood from healthy individuals was extracted using Qiagen Blood and tissue kit (# 69504). The DNA was eluted in 30ul DNase-free water and quantified on Qubit. 100ng of DNA was used for Sanger sequencing validation.

PCR amplification for Sanger DNA sequencing

For DNA sequencing, an 823 bp fragment of the NAT2 gene (819–1641 bp of the gene) was amplified using the forward primer 5′-GGGCTGTTCCCTTTGAGA-3′ and reverse primer 5′-TAGTGAGTTGGGTGATAC-3′. A 20 µl PCR mixture contained 0.5 µl of each forward and reverse primers from 10 µM stocks, 8 µl double distilled water, 0.5ul Phusion Taq polymerase and 1 µl (~100ng) DNA template. PCR was performed with initial denaturation at 95°C for 5 min followed by 30 cycles of denaturation at 95°C for 30 s, annealing at 55°C for 30 s and extension at 72°C for 1 min, with an additional extension at 72°C for 10 min. PCR products were analyzed on 1.5% agarose gels to confirm size of product which was then sequenced at the (Stanford PAN Facility, CA).

Primers and probes for melt curve analysis

Three sets of primers spanning the *NAT2* gene were used for single-plex and multiplex PCR. Primers and sloppy molecular beacon (SMB) probes were designed using Beacon Designer (Premier Biosoft International, Palo, CA; version 8). Three of 5 molecular beacon probes (NAT2-191, NAT2-590 and NAT2-857) were designed with 100% complementarity towards mutant alleles and two (NAT2-282 and NAT2-341) were 100% specific to wild type alleles. For single-plex assays, all probes were labelled with FAM at their 5’ end and BHQ-1 at 3’. For the multiplex assay on GeneXpert, FAM was replaced with other fluorophores except for NAT2-

590. A list of primers and probes sequences for the multiplex assay with their corresponding fluorophores and quenchers is provided in **Supplementary Table 4.**

Single-plex PCR and melt curve analysis on pulmonary TB patients

Genomic DNA extracted from sputum samples from TB positive patients was used for single-plex assays performed on StepOne Plus Real Time PCR. A 20ul total reaction volume was set up using 10ng genomic DNA per assay. PCR mastermix included (0.5 ul of 2U Aptataq exo-DNA polymerase, 1X betaine, 1X Aptataq buffer, 4mM MgCl2, 1X ROX passive reference dye, 60nM FP,1000nM reverse primers, 250uM of each probe). PCR was initiated by 10 min of denaturation–activation at 95°C, followed by 50 cycles at 95°C for 15 sec (denaturation), annealing at 60°C for 15 s and extension at 76°C for 20sec. The melting program included three steps: denaturation at 95°C for 1 min, followed by renaturation at 35°C for 3 min and a continuous reading of fluorescence from 45 to 85°C by heating at increments of 0.03°C/s. The MMCA curve was analyzed using the StepOne Plus software version 2.0. For single-plex melt curve assay validation, TaqMan 7-SNP genotyping assays were performed using commercial assays (NAT2 TaqMan® SNP Genotyping Assays, Applied Biosystems) on DNA extracted from sputum samples from 49 pulmonary TB patients on a StepOne Plus Real Time PCR machine.

Pharmacokinetic analysis of INH clearance in tuberculosis patients

The population PK analysis was performed using the non-linear mixed effects modeling approach using NONMEM (version 7.4.3; ICON plc, Gaithersburg, MD, USA), PsN and R-based Xpose (version 4.7 and higher)[49,50]. One-compartment model with a first-order absorption with a lognormal distribution for inter-individual variability (IIV) on different PK parameter(s)

as well as an additive and/or proportional model for the residual error were tested for the base model selection. Mixture models with two or three subpopulations representing different clearance rate were then evaluated. The first-order conditional estimation with interaction method (FOCEI) was applied and the model-building procedure and model selection was based on the log-likelihood criterion (the difference in the minimum OFV between hierarchical models was assumed to be Chi-square distributed with degrees of freedom equal to the difference in the number of parameters between models), goodness-of-fit plots (e.g. relevant residuals against time randomly distributed around zero), and scientific plausibility of the model. Visual predictive check was conducted to evaluate whether the final model with estimated fixed-effect parameters and covariates adequately describe data.

Automated NAT2-PGx Multiplex PCR and melt curve analysis

Asymmetric PCR and melt curve analysis were performed on a GeneXpert IV instrument using GeneXpert Dx 4.8 software (Cepheid, Sunnyvale). Flex cartridge-01 (Cepheid) were used to perform automated DNA extraction from whole blood followed by PCR amplification and melt curve analysis to detect SNPs. PCR and melt conditions were optimized using mastermix prepared in house. The NAT2-PGx assay was performed in an 80ul reaction volume (70ul mastermix and 10ul eluted DNA). Briefly, 100ul of whole blood was mixed with 900ul of lysis buffer (Cepheid) in a 1.5ml Eppendorf tube. The sample was vortexed for 2-3 sec and incubated at room temperature for 2min. The entire 1ml whole blood and lysis buffer mix was loaded into sample preparation chamber of flex cart-01 for automated DNA extraction. 70ul PCR mastermix was simultaneously loaded in the PCR reaction chamber of the flex cart-01. The GeneXpert was programmed to elute DNA in 10ul volume which was used for the NAT2-PGx assay. PCR

mastermix included (2ul of 2U Aptataq exo-DNA polymerase, 1X Betaine, 1X PCR additive reagent, 1X Aptataq buffer, 8mM MgCl2, 400nM FP, 900nM reverse primers, 500nM of 191-Cy5.5 and 857-Alexa-405, 430nM 282-Alexa-647 and 590-FAM and 300nM 341-Alexa-537 probes). PCR was initiated at holding stage- 50°C for 2min, initial denaturation at 94°C for 2min, followed by 50 cycles of denaturation at 95°C for 15 sec, annealing at 57°C for 30 sec and extension at 65°C for 60 sec. The melting program included three steps: denaturation at 95°C for 1 min, followed by renaturation at 40°C for 3 min and a continuous reading of fluorescence from 40 to 72°C by heating at increments of 0.05°C/sec. The MMCA curve was analyzed using the GXP version 4.8 software.

We validated the automated NAT2-PGx assay by analyzing 20 blood samples, for which polymorphisms in the 5 positions were confirmed by Sanger sequencing. We assessed analytical sensitivity of the assay and robustness to input blood volume by performing it on varying volumes of whole blood (200 ul, 100 ul, 50 ul, 25 ul) and comparing the Tm results and standard deviation for each position across blood volumes.

Funding

FleXcartridges and technical support for their use were provided by Cepheid. This study was supported by the Institute for Immunity, Transplantation, and Infection and the Department of Medicine at Stanford University.

Reporting summary. Further information on research design is available in the Nature Research Reporting Summary linked to this article.

Data availability

Data supporting the findings of this manuscript are available in the Supplementary Information files or from the corresponding author upon request.

Code availability

Code and dataset used to develop NAT2 classifier are provided with the manuscript.

Acknowledgements

We thank Veronique Dartois for performing the plasma drug level assays.

Author contributions

JRA and RV conceived of the study. RV, JC, and JRA designed the experiments. RV, SP, FMM, MTV, ASS and JC collected data. RV, NZ, RS and JRA analyzed data. EW, DG and DP provided technical guidance on the assay development. RV and JRA wrote the first draft of the manuscript, and all authors contributed to the final version.

Conflicts of Interest

JRA and RV are named co-inventors on a provisional patent (Application number 62/991,477) for a *NAT2* pharmacogenomic assay.

References

1. Gillespie SH. et al. Consortium. Four-month moxifloxacin-based regimens for drug-sensitive tuberculosis. N Engl J Med. 2014 Oct 23;371(17):1577-87.
2. Merle CS. et al. OFLOTUB/Gatifloxacin for Tuberculosis Project. A four-month gatifloxacin-containing regimen for treating tuberculosis. N Engl J Med. 2014 Oct 23;371(17):1588-98.
3. Jindani A. et al. High-dose rifapentine with moxifloxacin for pulmonary tuberculosis. N Engl J Med. 2014 Oct 23;371(17):1599-608.
4. Pratt VM. et al. Characterization of 137 Genomic DNA Reference Materials for 28 Pharmacogenetic Genes: A GeT-RM Collaborative Project. J Mol Diagn. 2016 Jan;18(1):109-23.
5. García-Martín E. Interethnic and intraethnic variability of NAT2 single nucleotide polymorphisms. Curr Drug Metab. 2008 Jul;9(6):487-97.
6. Schaberg T et al. Risk factors for side-effects of isoniazid, rifampin and pyrazinamide in patients hospitalized for pulmonary tuberculosis. Eur Respir J. 1996 Oct;9(10):2026-30.
7. Saukkonen JJ. et al. Hepatotoxicity of Antituberculosis Therapy Subcommittee. An official ATS statement: hepatotoxicity of antituberculosis therapy. Am J Respir Crit Care Med. 2006 Oct 15;174(8):935-52.
8. Schutz C. et al. Burden of antituberculosis and antiretroviral drug-induced liver injury at a secondary hospital in South Africa. S Afr Med J. 2012 Mar 2;102(6):506-11.
9. Luzze H. et al. Relapse more common than reinfection in recurrent tuberculosis 1-2 years post treatment in urban Uganda. Int J Tuberc Lung Dis. 2013 Mar;17(3):361-7

10. Romanowski K. et al. Predicting tuberculosis relapse in patients treated with the standard 6-month regimen: an individual patient data meta-analysis. Thorax. 2019 Mar;74(3):291-297.
11. Pasipanodya JG. et al. Meta-analysis of clinical studies supports the pharmacokinetic variability hypothesis for acquired drug resistance and failure of antituberculosis therapy. Clin Infect Dis. 2012 Jul;55(2):169-77.
12. Gumbo T. et al. Isoniazid bactericidal activity and resistance emergence: integrating pharmacodynamics and pharmacogenomics to predict efficacy in different ethnic populations. Antimicrob Agents Chemother. 2007 Jul;51(7):2329-36.
13. Pasipanodya JG. et al. Serum drug concentrations predictive of pulmonary tuberculosis outcomes. J Infect Dis. 2013 Nov 1;208(9):1464-73.
14. Kinzig-Schippers M, Tomalik-Scharte D, Jetter A, Scheidel B, Jakob V, Rodamer M, Cascorbi I, Doroshyenko O, Sörgel F, Fuhr U. Should we use N-acetyltransferase type 2 genotyping to personalize isoniazid doses? Antimicrob Agents Chemother. 2005 May;49(5):1733-8.
15. Sabbagh A. et al. Worldwide distribution of NAT2 diversity: implications for NAT2 evolutionary history. BMC Genet. 2008 Feb 27;9:21.
16. Wang PY. et al. NAT2 polymorphisms and susceptibility to anti-tuberculosis drug-induced liver injury: a meta-analysis. Int J Tuberc Lung Dis. 2012 May;16(5):589-95.
17. Du H. et al. Slow N-acetyltransferase 2 genotype contributes to anti-tuberculosis drug-induced hepatotoxicity: a meta-analysis. Mol Biol Rep. 2013 May;40(5):3591-6.
18. Azuma J. et al. Pharmacogenetics-based tuberculosis therapy research group. NAT2 genotype guided regimen reduces isoniazid-induced liver injury and early treatment

failure in the 6-month four-drug standard treatment of tuberculosis: a randomized controlled trial for pharmacogenetics-based therapy. Eur J Clin Pharmacol. 2013 May;69(5):1091-101.

19. Snider DE Jr. et al. Isoniazid-associated hepatitis deaths: a review of available information. Am Rev Respir Dis. 1992 Feb;145(2 Pt 1):494-7.
20. Kuznetsov IB. et al. A web server for inferring the human N-acetyltransferase-2 (NAT2) enzymatic phenotype from NAT2 genotype. Bioinformatics. 2009 May 1;25(9):1185-6.
21. Ramachandran G. et al. Role of pharmacogenomics in the treatment of tuberculosis: a review. Pharmgenomics Pers Med. 2012;5:89-98.
22. McInnes G. et al. Drug Response Pharmacogenetics for 200,000 UK Biobank Participants. doi: https://doi.org/10.1101/2020.08.09.243311
23. Rens NE. et al. Cost-Effectiveness of a Pharmacogenomic Test for Stratified Isoniazid Dosing in Treatment of Active Tuberculosis. Clin Infect Dis. 2020 Jan 6:ciz1212.
24. Sabbagh A. et al. Evaluating NAT2PRED for inferring the individual acetylation status from unphased genotype data. BMC Med Genet. 2009 Dec 31;10:148.
25. Sabbagh A. et al. Arylamine N-acetyltransferase 2 (NAT2) genetic diversity and traditional subsistence: a worldwide population survey. PLoS One. 2011 Apr 6;6(4):e18507.
26. Van Oosterhout JJ. et al. Pharmacokinetics of Antituberculosis Drugs in HIV-Positive and HIV-Negative Adults in Malawi. Antimicrob Agents Chemother. 2015 Oct;59(10):6175-80.
27. Wilkins JJ. et al. Variability in the population pharmacokinetics of isoniazid in South African tuberculosis patients. Br J Clin Pharmacol. 2011 Jul;72(1):51-62.

28. Wilkins JJ. et al. Population pharmacokinetics of rifampin in pulmonary tuberculosis patients, including a semimechanistic model to describe variable absorption. Antimicrob Agents Chemother. 2008 Jun;52(6):2138-48.
29. Wilkins JJ. et al. Variability in the population pharmacokinetics of pyrazinamide in South African tuberculosis patients. Eur J Clin Pharmacol. 2006 Sep;62(9):727-35.
30. Iselius L. et al. Formal genetics of isoniazid metabolism in man. Clin Pharmacokinet. 1983 Nov-Dec;8(6):541-4.
31. Evans DA. Genetic variations in the acetylation of isoniazid and other drugs. Ann N Y Acad Sci. 1968 Jul 31;151(2):723-33.
32. Evans DA. An improved and simplified method of detecting the acetylator phenotype. J Med Genet. 1969 Dec;6(4):405-7.
33. Donald PR. et al. The influence of dose and N-acetyltransferase-2 (NAT2) genotype and phenotype on the pharmacokinetics and pharmacodynamics of isoniazid. Eur J Clin Pharmacol. 2007 Jul;63(7):633-9.
34. Lee SW. et al. NAT2 and CYP2E1 polymorphisms and susceptibility to first-line anti-tuberculosis drug-induced hepatitis. Int J Tuberc Lung Dis. 2010 May;14(5):622-6.
35. Roy B. et al. Predisposition of antituberculosis drug induced hepatotoxicity by cytochrome P450 2E1 genotype and haplotype in pediatric patients. J Gastroenterol Hepatol. 2006 Apr;21(4):784-6.
36. Simon T. et al. Combined glutathione-S-transferase M1 and T1 genetic polymorphism and tacrine hepatotoxicity. Clin Pharmacol Ther. 2000 Apr;67(4):432-7.
37. Strange RC. et al. Glutathione S-transferase: genetics and role in toxicology. Toxicol Lett. 2000 Mar 15;112-113:357-63.

504 38. Ramachandran G. et al. Role of pharmacogenomics in the treatment of tuberculosis: a
505 review. Pharmgenomics Pers Med. 2012;5:89-98.
506 39. Mukonzo JK. et al. Role of pharmacogenetics in rifampicin pharmacokinetics and the
507 potential effect on TB-rifampicin sensitivity among Ugandan patients. Trans R Soc Trop
508 Med Hyg. 2020 Feb 7;114(2):107-114.
509 40. Naidoo A. et al. Effects of genetic variability on rifampicin and isoniazid
510 pharmacokinetics in South African patients with recurrent tuberculosis.
511 Pharmacogenomics. 2019 Mar;20(4):225-240.
512 41. Medellin-Garibay SE. et al. A population approach of rifampicin pharmacogenetics and
513 pharmacokinetics in Mexican patients with tuberculosis. Tuberculosis (Edinb). 2020
514 Sep;124:101982.
515 42. *Database of arylamine N-acetyltransferases* (http://nat.mbg.duth.gr)
516 43. Clinical trial of six-month and four-month regimens of chemotherapy in the treatment of
517 pulmonary tuberculosis. Am Rev Respir Dis. 1979 Apr;119(4):579-85.
518 44. Haley CA. Treatment of Latent Tuberculosis Infection. Microbiol Spectr. 2017 Apr;5(2).
519 45. Kuhn M. et al. (2019). caret: Classification and Regression Training. R package version
520 6.0-84. https://CRAN.R-project.org/package=caret
521 46. Prideaux B. et al. The association between sterilizing activity and drug distribution into
522 tuberculosis lesions. Nat Med. 2015 Oct;21(10):1223
523 47. Walter ND. et al. Transcriptional Adaptation of Drug-tolerant Mycobacterium
524 tuberculosis During Treatment of Human Tuberculosis. J Infect Dis. 2015 Sep
525 15;212(6):990-8.

526 48. Chomczynski P. A reagent for the single-step simultaneous isolation of RNA, DNA and
527 proteins from cell and tissue samples. Biotechniques. 1993 Sep;15(3):532-4, 536-7.
528 49. Beal SL. Et al. NONMEM 7.4 Users Guides. (1989– 2019). ICON plc, Gaithersburg,
529 MD. https://nonmem.iconplc.com/nonmem744
530 50. Lindbom L. et al. (2004). Perl-speaks-NONMEM (PsN)--a Perl module for NONMEM
531 related programming. *Comput Methods Programs Biomed*, *75* (2), 85-94.

532
533
534
535

536 **Figure 1. Predicted *NAT2* phenotype from sputum samples and associated acetylation ratio**
537 **and isoniazid clearance rates from patients receiving tuberculosis treatment.** The (a) 8 hour
538 acetyl-INH to INH ratio and (b) isonazid clearance rates, according to acetylation phenotype
539 predicted from 5 SNPs, measured in sputum samples from 49 patients receiving treatment for
540 active tuberculosis.
541
542 **Figure 2. Schemata for the automated NAT2 Pharmacogenomic assay**. 1-2 drops of blood is
543 collected in an Eppendorf tube and mixed with lysis buffer to a total of 1 ml, which is then
544 loaded onto a GeneXpert Flex01 cartridge and placed into a GeneXpert instrument for automated
545 DNA extraction, asymmetric PCR and meltcurve analysis. Allele patterns for each of the 5 SNPs
546 are determined by Tm analysis, and the resulting data are used to predict acetylator phenotype.
547
548 **Figure 3. Negative derivative transformed melt curves for the five NAT2 gene**
549 **polymorphisms**. The shift in melt curve temperature is observed during a nucleotide exchange.
550 Sloppy molecular beacon probes are first hybridized and then melted off of their NAT2 target
551 amplicon. The melt curves indicate wild type alleles at positions 191(red), 341(green) and 857
552 (orange); and mutant alleles at positions 282(Blue) and 590(Purple).
553
554 **Figure 4. Effect of whole blood sample volume on melting temperature for wild type and**
555 **mutant alleles at 5 positions in *NAT2*:** *NAT2* polymorphisms were accurately detected at all
556 volumes with sufficient different in melting temperature (Tm) to distinguish wild type from
557 mutant alleles. No individuals in this dataset had mutations at position 191.
558

559 **Table 1. Summary of populations included in genomic analysis and their acetylation**

560 **genotypes.**

561

		Acetylation Genotype, n (%)		
Region	**Number of individuals**	**Slow**	**Intermediate**	**Rapid**
Americas	1,112	432 (39%)	463 (42%)	217 (20%)
Central and South Asia	588	355 (60%)	198 (34%)	35 (6%)
East Asia	2,308	340 (15%)	1049 (45%)	919 (40%)
Europe	3,458	1966 (57%)	1249 (36%)	243 (7%)
North Africa	44	30 (68%)	10 (23%)	4 (9%)
sub-Saharan Africa	1,051	450 (43%)	459 (44%)	142 (14%)
Total	8,561	3573 (42%)	3428 (40%)	1560 (18%)

562

563

564 **Table 2. Out-of-sample prediction accuracy of unphased NAT2 SNP data for acetylation**
565 **phenotype in random forest models.** Models were trained with 5,738 individuals and tested on
566 2,823 individuals. Sens: sensitivity. Spec: specificity.
567

NAT2 SNP Positions	SNP number	Accuracy	95% CI	Sens. Rapid	Spec. Rapid	Sens. Slow	Spec Slow
191, 282, 341, 481, 590, 803, 857	7	1.000	(0.999-1.000)	1.000	1.000	1.000	1.000
191, 282, 341, 481, 590, 857	6	1.000	(0.999-1.000)	1.000	1.000	1.000	1.000
191, 282, 341, 590, 857	5	1.000	(0.999-1.000)	1.000	1.000	1.000	1.000
282, 341, 590, 857	4	0.978	(0.972-0.983)	0.996	0.988	0.969	0.999
341, 590, 847	3	0.976	(0.970-0.982)	1.000	0.986	0.967	1.000
341, 590	2	0.852	(0.838-0.865)	1.000	0.889	0.832	1.000

568
569
570
571
572
573
574

575 **Table 3. Melting temperature (Tm) values for five NAT2 polymorphisms derived from**

576 **DNA-probe hybrid melts using single-plex assays validated on 49 pulmonary TB patients**

577

	Mutant	**Wild type**	**Het**	**Mutant**	**Wild type**	
NAT2 SNP position	Total samples analyzed	Total samples analyzed	Total samples analyzed	Tm ± SD	Tm ± SD	ΔTm (WT-MT)
191	0	44	5	66.3 ± 0.28	61.92 ± 0.68	4.38
282	6	24	19	62.81 ± 0.40	66.85 ± 0.34	4.04
341	12	23	14	66.30± 0.48	68.70 ± 0.38	2.40
590	0	35	14	68.0 ± 0.28	64.37 ± 0.28	3.63
857	1	41	7	66.4± 0.11	62.72 ± 0.29	3.68

578 SD: Standard deviation

579

Supplementary Table 1. *NAT2* polymorphism profiles of 49 pulmonary TB patients detected from 5-SNP and 7-SNP genotyping assays. Acetylator phenotypes predicted from 5-SNP, 6-SNP and 7-SNP classifiers and plasma INH and acetyl-INH levels recorded at various time-points.

Supplementary Table 2. (a) NAT2 genotype of whole blood samples (n=20) analyzed on 5-plex NAT2-PGx assay and validated on Sanger sequencing. **(b)** NAT2 genotypes of ten whole blood samples analyzed using 200ul, 100ul, 50ul and 25ul samples

Supplementary Table 3. Population information on the dataset used to develop 5-SNP classifier.

Supplementary Table 4. List of primers and probes sequences for multiplex assay with their corresponding fluorophores and quenchers

A



B



① Sample collection



Collect 1-2 drops of whole blood (approx. 50ul)

② Whole blood pretreatment



Mix 950ul lysis buffer, vortex for 2 sec and incubate at RT for 2min

③ Flex cart01 preparation

Pipette 1ml pretreated sample and 70ul PCR mastermix into the cartridge

④ Automated DNA extraction & qPCR

Total run time= 140min

Load the cartridge in the GeneXpert machine and start the run

⑤ Data aquisition



Acquire melt curve data for NAT2 gene polymorphism detection

⑥ INH acetylator phenotype prediction



Upload NAT2 polymorphism data on phenotype prediction algorithm